Anti-Human EGFR Recombinant Antibody (Zalutumumab) (CAT#: TAB-040)

Recombinant monoclonal antibody to EGFR. Zalutumumab (proposed trade name HuMax-EGFr) is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFr). the Netherlands. Specifically, zalutumumab is designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN), a type of cancer. The current treatment for SCCHN includes tyrosine kinase inhibitors and human monoclonal antibodiess. In addition, murine mAbs were tested successfully in mice, but caused an immune response in humans and were thus determined as ineffective in therapeutics.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Development of a panel of EGFR-specific mAbs with distinct functionalities.

Figure 1 Development of a panel of EGFR-specific mAbs with distinct functionalities.

A, Binding of zalutumumab, zalu-N297Q, mAb 018, and mAb 018-N297Q to cell-associated EGFR on A431 cells analyzed by flow cytometry; data were analyzed using a four-parameter logistic curve fit. Shown is the mean fluorescence intensity (MFI). B, The capacity of the different mAbs to induce ADCC analyzed in a 51Cr-release assay using human PBMCs as effector cells and A431 cells as target cells. Data shown are percentages specific lysis, calculated as described in Materials and Methods. C, mAb-induced inhibition of EGFR phosphorylation in A431 cells upon stimulation with EGF measured in an EGFR phosphorylation inhibition assay. Data shown are time-resolved fluorescences (TRF). D, Inhibition of A431 cell proliferation determined in a proliferation inhibition assay using Alamar Blue staining. Each data point represents mean ± SEM of triplicates, and experiments shown are representative of at least two independent experiments.

Overdijk, M. B., Verploegen, S., van den Brakel, J. H., van Bueren, J. J. L., Vink, T., van de Winkel, J. G., ... & Bleeker, W. K. (2011). Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. The Journal of Immunology, 1003926.

Figure 2 Zalutumumab and mAb 018 are functional in an ADCC assay with murine effector cells.

Figure 2 Zalutumumab and mAb 018 are functional in an ADCC assay with murine effector cells.

The capacity of the different mAbs to induce ADCC was analyzed in a 51Cr-release assay using mouse bone marrow-derived macrophages as effector cells, and A431 cells as target cells. mAbs were tested at a concentration of 10 μg/ml with six replicates. Data represent mean ± SEM of three independent experiments.

Overdijk, M. B., Verploegen, S., van den Brakel, J. H., van Bueren, J. J. L., Vink, T., van de Winkel, J. G., ... & Bleeker, W. K. (2011). Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. The Journal of Immunology, 1003926.

Figure 3 Both zalutumumab and mAb 018 are capable of inhibiting growth of tumor cells expressing mutant KRAS.

Figure 3 Both zalutumumab and mAb 018 are capable of inhibiting growth of tumor cells expressing mutant KRAS.

Eight mice per group were inoculated s.c. with 1 × 106 A431-KRAS4bG12V cells, which are insensitive for EGFR signaling inhibition. A, Single treatment at day 0 with 5 mg/kg mAb. B, Single treatment at day 0, at indicated dose levels. Data shown are mean tumor volumes ± SEM.

Overdijk, M. B., Verploegen, S., van den Brakel, J. H., van Bueren, J. J. L., Vink, T., van de Winkel, J. G., ... & Bleeker, W. K. (2011). Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. The Journal of Immunology, 1003926.

Figure 4 Histology and immunohistochemistry of biopsies from zalutumumab-injected skin treated with HuMab-10F8 or untreated.

Figure 4 Histology and immunohistochemistry of biopsies from zalutumumab-injected skin treated with HuMab-10F8 or untreated.

Data shown are representative sections of skin biopsies of one subject for part III of the study. Biopsies were taken at day 14 after two injections with 100 µg of zalutumumab with [A, C, E, G, I, K] or without HuMab-10F8 [B, D, F, H, J, L]. A, B: HE staining; C, D: staining for EGFR; E–H: staining for macrophages and I–L: staining for neutrophils. Extensive influx of inflammatory cells in the vicinity of the hair follicle with histological signs of folliculitis was observed in zalutumumab-injected skin (right panels), whereas in the zalutumumab-injected skin treated with HuMab-10F8 (left panels) inflammatory cells were virtually absent and sebaceous glands and hair follicles showed normal histological features. Inflammatory infiltrate in the zalutumumab-injected skin was mainly composed of neutrophils (neutrophil elastase positive cells, J, L) and to a lesser extent of macrophages; (CD68 positive cells F, H). Scale bars are 100 µm (A–F, I, J) and 20 µm (G, H, K, L). G, H, K and L are magnifications of the squared areas indicated in E, F, I and J.

Bangsgaard, N., Houtkamp, M., Schuurhuis, D. H., Parren, P. W., Baadsgaard, O., Niessen, H. W., & Skov, L. (2012). Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor. PLoS One, 7(6), e39706.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG1 - kappa
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • ELISA, FC, IP, FuncS, IF, Neut, ICC
  • Trade name
  • humax-egfr
  • CAS
  • 667901-13-5
  • Generic Name
  • Zalutumumab
  • MW
  • 148 kDa
  • Related Disease
  • Head and neck cancers

Product Property

  • Purity
  • >95.0% as determined by analysis by SDS-PAGE.
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • The EGFR antibody has been reported in applications of FC, ADCC, Inhib, IHC.

Target

  • Alternative Names
  • Zalutumumab;humax-egfr;667901-13-5;HuMax-EGFR;2F8;EGFR;epidermal growth factor receptor;epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog) , ERBB;ERBB1;erythroblastic leukemia viral (v erb b) oncogene homolog

Related Resources

  • Biosimilar Overview
  • Related Diseases
  • Related Signaling Pathways
Please refer to Zalutumumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Zalutumumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Zalutumumab"

Afuco™ Anti-EGFR ADCC Recombinant Antibody (Zalutumumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to EGFR. Zalutumumab (proposed trade name HuMax-EGFr) is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFr).

See other products for "EGFR"

Humanized Antibody

Chimeric Antibody

CAT Product Name Application Type
TAB-H49 Anti-Human EGFR Recombinant Antibody (Modotuximab) FuncS, IF, Neut, ELISA, FC, IP, IHC IgG1 - kappa
TAB-0225CL-F(E) Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-0225CL-F(E)) Block, Inhib, FuncS, Apop, In vivo Chimeric (Mouse/Human) Fab
TAB-272MZ-F(E) Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-272MZ-F(E)) FuncS Chimeric (mouse/human) Fab
TAB-302MZ-F(E) Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-302MZ-F(E)) ELISA Chimeric (mouse/human) Fab
TAB-308MZ-F(E) Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-308MZ-F(E)) ELISA, FC Chimeric antibody (mouse/human)

Fc Glycosylation

High-mannose Glycoform

CAT Product Name Application Type
Gly-055LC-1 Recombinant Anti-Human EGFR Antibody (Fc glycosylation/High-mannose glycosylated) ELISA Chimeric antibody (mouse/human)

Deglycosylated Antibody (Non-glycosylated IgGs)

CAT Product Name Application Type
Gly-167LC Recombinant Anti-Human EGFR Antibody (Non-glycosylated) ELISA Human antibody

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0183MZ Chicken Anti-EGFR Polyclonal IgY WB Chicken antibody
BRD-0668MZ Chicken Anti-EGFR Polyclonal IgY WB Chicken antibody

Neutralizing Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-165 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Matuzumab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody
AFC-TAB-464CQ Afuco™ Anti-EGFR ADCC Recombinant Antibody (Tomuzotuximab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody
AFC-TAB-003 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Cetuximab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-040 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Zalutumumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody
AFC-TAB-119 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Necitumumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody

Submit a review or a question
There are currently no Customer reviews or questions for TAB-040. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare